Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Cingulate Inc (CING)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cingulate's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.874 -0.006    -0.68%
06:00:29 - Closed. Currency in USD ( Disclaimer )
After Hours
0.864
-0.010
-1.144%
8:22:24 - Real-time Data
  • Volume: 20,717
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.841 - 0.890
Type:  Equity
Market:  United States
Cingulate 0.874 -0.006 -0.68%

Cingulate Inc Company Profile

 
Get an in-depth profile of Cingulate Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

15

Equity Type

ORD

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

Contact Information

Address 1901 West 47th Place
Kansas City, 66205
United States
Phone 913 942 2300
Fax -

Top Executives

Name Age Since Title
Brian D. Barash - - Member of Scientific Advisory Board
Andrew J. Cutler - - Member of Scientific Advisory Board
John S. Markowitz - - Member of Scientific Advisory Board
Alice Mao - - Member of Scientific Advisory Board
Ann Childress - - Member of Scientific Advisory Board
Sharon B. Wigal - - Member of Scientific Advisory Board
Peter J. Werth 84 2018 Director
Declan Quinn - - Member of Scientific Advisory Board
Ignacio Herman Valdes - - Member of Scientific Advisory Board
Dinohra Munoz-Silva - - Member of Scientific Advisory Board
Jeffrey S. Ervin 46 2024 Director
Bryan Jay Lawrence 58 2024 Director
Jeffrey Newcorn - - Member of Scientific Advisory Board
Laurence L. Greenhill - - Member of Scientific Advisory Board
John A. Roberts 65 2024 Independent Director
Shane J. Schaffer 49 2012 CEO & Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CING Comments

Write your thoughts about Cingulate Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email